Department of Medicine, Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Expert Rev Anticancer Ther. 2013 Sep;13(9):1081-8. doi: 10.1586/14737140.2013.829641.
Multiple myeloma (MM) has been mostly incurable due to its highly complex and heterogeneous molecular abnormalities and the support from myeloma microenvironment factors. A therapeutic strategy which effectively targets relevant and specific molecule to myeloma cells, and which is potent in overcoming tumor microenvironment-mediated drug resistance needs to be developed. One of the promising fields is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This review focuses on the basic and clinical aspects of two emerging and promising novel MoAbs for MM, elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are relatively specific to myeloma cells and expressed in more than 90% of MM patients, and mediate adhesion of myeloma cells to bone marrow stromal cells. We also discuss the unique characteristics of the two MoAbs by comparing with other MoAbs being developed for MM.
多发性骨髓瘤（MM）由于其高度复杂和异质性的分子异常以及骨髓瘤微环境因素的支持，大多数情况下是不可治愈的。需要开发一种有效的治疗策略，该策略可以针对骨髓瘤细胞中的相关和特定分子，并且能够有效克服肿瘤微环境介导的耐药性。一个有前途的领域是使用针对骨髓瘤特异性抗原的单克隆抗体（MoAbs）进行免疫治疗。本综述重点介绍了两种新兴的、有前途的针对 MM 的新型 MoAbs 的基础和临床方面，即针对 CS1 的 elotuzumab 和针对 CD38 的 daratumumab。这两种抗原相对特异于骨髓瘤细胞，在超过 90%的 MM 患者中表达，并介导骨髓瘤细胞与骨髓基质细胞的黏附。我们还通过比较正在开发用于 MM 的其他 MoAbs 来讨论这两种 MoAbs 的独特特征。
